koto_feja/E+ via Getty Images
- BioLineRx (NASDAQ:BLRX) completed enrollment in a phase 1/2a study of its potential intratumoral cancer vaccine AGI-134 in patients with unresectable metastatic solid tumors.
- The company expects results of the study — which enrolled 38 patients in the U.K., Spain and Israel — in H1 2022.
- BLRX -1.64% premarket to $1.80.